UNSPSC 51184007: Gliclazide

This classification denotes an anti-diabetic agent with the molecular formula C15H21N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) G4PX8C4HKV, chemically known as urea, 1-(hexahydrocyclopenta(c)pyrrol-2(1h)-yl)-3-(p-tolylsulfonyl)- but more generally known as gliclazide, which bears US NIH Compound Identifier 3475. European Medicines Agency schedules Gliclazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07921MIG.

UNSPSC 51184007 Gliclazide is a Commodity code representing a specific diabetes medication actively procured through cooperative purchasing arrangements by state and local health systems. State and local governments buy gliclazide as part of broader pharmaceutical supply agreements covering multiple generic drugs and over-the-counter products distributed across state agency facilities, correctional institutions, public health departments, and other government-operated health services. The work involves manufacturers and pharmaceutical suppliers establishing contractual relationships with authorized wholesalers to deliver specified National Drug Codes at negotiated prices, with vendors responsible for compliance with cGMP standards, DSCSA supply-chain security requirements, and FDA regulations. Procurement is typically managed through multistate cooperative purchasing alliances that aggregate demand across member jurisdictions to achieve volume pricing and simplified contracting, rather than through individual state or local RFPs.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic pharmaceuticals including gliclazide and other medications for distribution across participating state and local facilities in Minnesota, Oregon, and other member states. Vendors must maintain relationships with at least two of three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with functioning chargeback systems, demonstrate cGMP and DSCSA compliance, maintain $5 million in commercial general liability insurance, and accept a 3 percent administrative fee on all contract purchases. Contracts awarded by May 15, 2026, will be effective July 1, 2026, for an initial two-year term with optional extensions at MMCAP's discretion; evaluation is weighted 75 percent on price competitiveness, 10 percent on fixed pricing structure, and 5 percent each on administrative compliance, EDI capability, and acceptance of the administrative fee requirement.